Xinhua Silk Road: Revitalizing World Heritage fuels tourism market in SE. China’s historical city of Quanzhou

Lazare Eloundou Assomo, director of UNESCO World Heritage Center, recently led a delegation to visit Quanzhou, a historical port city in southeast China's Fujian Province, making the city, recognized as the “Emporium of the World in Song-Yuan China”, once again capture global attention. https://mma.prnewswire.com/media/2829252/photo.jpg While the global recognition of World Heritage is breathing new vitality […]

Levi & Korsinsky Urges Molina (MOH) Shareholders to Act Before Lead Plaintiff Deadline December 2, 2025

NEW YORK, NY / ACCESS Newswire / November 20, 2025 / If you suffered a loss on your Molina Healthcare, Inc. (NYSE:MOH) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/molina-healthcare-inc-lawsuit-submission-form?prid=178477&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

JHX INVESTOR ALERT: James Hardie Industries plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

(NYSE:JHX), SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of James Hardie Industries plc (NYSE: JHX) common stock (previously American Depositary Shares until their conversion to common stock on July 1, 2025) between May 20, 2025 and August 18, 2025,

JHX INVESTOR ALERT: James Hardie Industries plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

JHX INVESTOR ALERT: James Hardie Industries plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law GlobeNewswire November 21, 2025 SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of James Hardie Industries plc (NYSE: JHX)

BANDAI SPIRITS to Merchandise the ONE PIECE × NBA Collaboration

The first figure in the series is a dunk figure of Luffy in an NBA uniform, scheduled for release in December 2025 BANDAI SPIRITS Co., Ltd. (President and CEO: Sakakibara Hiroshi, headquarters: Minato-ku, Tokyo) is announcing a collaboration between the globally popular TV anime “ONE PIECE” and the NBA. The first commemorative product, “ONE PIECE

BANDAI SPIRITS to Merchandise the ONE PIECE × NBA Collaboration

The first figure in the series is a dunk figure of Luffy in an NBA uniform, scheduled for release in December 2025 BANDAI SPIRITS Co., Ltd. (President and CEO: Sakakibara Hiroshi, headquarters: Minato-ku, Tokyo) is announcing a collaboration between the globally popular TV anime “ONE PIECE” and the NBA. The first commemorative product, “ONE PIECE

BANDAI SPIRITS to Merchandise the ONE PIECE × NBA Collaboration

The first figure in the series is a dunk figure of Luffy in an NBA uniform, scheduled for release in December 2025 BANDAI SPIRITS Co., Ltd. (President and CEO: Sakakibara Hiroshi, headquarters: Minato-ku, Tokyo) is announcing a collaboration between the globally popular TV anime “ONE PIECE” and the NBA. The first commemorative product, “ONE PIECE

BANDAI SPIRITS to Merchandise the ONE PIECE × NBA Collaboration

The first figure in the series is a dunk figure of Luffy in an NBA uniform, scheduled for release in December 2025 BANDAI SPIRITS Co., Ltd. (President and CEO: Sakakibara Hiroshi, headquarters: Minato-ku, Tokyo) is announcing a collaboration between the globally popular TV anime “ONE PIECE” and the NBA. The first commemorative product, “ONE PIECE

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

(NASDAQ:IKT), WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire November 21, 2025 WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of

Scroll to Top